Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies
Antibodies · 05.12.2025 · 14 (4) · 104
DOI: 10.3390/antib14040104 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 05.12.2025. Verfasst von Giuseppe Lauletta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Head and neck dermatitis (HND) represents a challenging phenotype of atopic dermatitis (AD), often showing suboptimal response or paradoxical worsening during biologic therapy.
Objective
To review the efficacy and safety of current systemic treatments for HND, with a focus on dupilumab, tralokinumab, lebrikizumab, and janus kinase (JAK) inhibitors.
Methods
We conducted a narrative review of randomized controlled trials, post hoc analyses, and real-world studies assessing clinical outcomes in patients with moderate-to-severe AD involving the head and neck. Outcomes included Eczema Area and Severity Index (EASI) H&N subscore, erythema grade, patient-reported measures, and adverse events.
Results
Dupilumab shows substantial efficacy for HND in both clinical trials and real-life studies; however, responses are often less pronounced than in other anatomical regions, and facial redness (FR) has emerged as a notable adverse event in up to 9% of patients. Tralokinumab and lebrikizumab demonstrate significant improvements in HND involvement, with low incidence of paradoxical reactions. JAK inhibitors, particularly upadacitinib, provide rapid and marked improvement in refractory cases and in patients developing FR during biologic therapy.
Conclusions
Systemic therapy for HND should be individualized, balancing efficacy and tolerability. JAK inhibitors represent a valuable alternative in biologic-refractory phenotypes or in patients experiencing dupilumab-associated FR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy.
- Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, 86100 Campobasso, Italy.
- Dermatology Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60121 Ancona, Italy.
ORCID-Profile: Giuseppe Lauletta, Cataldo Patruno, Claudio Brescia, Valentina Ventura, Maddalena Napolitano
Zitieren
APA
Lauletta, G., Patruno, C., Brescia, C., Cosenza, A., D'Elia, C., Ventura, V., Martina, E., & Napolitano, M. (2025). Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies. Antibodies, 14(4), 104. https://doi.org/10.3390/antib14040104
Vancouver
Lauletta G, Patruno C, Brescia C, Cosenza A, D'Elia C, Ventura V, et al. Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies. Antibodies. 2025;14(4):104. doi:10.3390/antib14040104
BibTeX
@article{Lauletta2025,
author = {Lauletta, Giuseppe and Patruno, Cataldo and Brescia, Claudio and Cosenza, Andrea and D'Elia, Carolina and Ventura, Valentina and Martina, Emanuela and Napolitano, Maddalena},
title = {Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies},
journal = {Antibodies},
year = {2025},
volume = {14},
number = {4},
pages = {104},
doi = {10.3390/antib14040104}
}
EUVIMED